AFM

Across TCGA pan-cancer cohorts, AFM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AFM data layer compared with 17 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AFM mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AFM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where AFM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.785	0.123	.009	27	view →
HNSC	DFS	Tertile	All	0.889	0.355	.010	15	view →
LUAD	OS	Median	II,III,IV	0.795	1.000	.005	11	view →
LSCC	OS	Tertile	All	0.965	1.000	.043	4	view →
GBM	OS	Median	All	0.872	0.663	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AFM–CCRCC (OS)

Open the CCRCC breakdown →